About StrataStem Ltd
StrataStem is an innovative spin-out biotech working at the forefront of Alzheimer's disease (AD) research and is developing intelligent phenotype-genotype (iPG) drug screening platforms to identify appropriate therapeutics for AD. We use induced Pluripotent Stem Cells (iPSCs) derived from AD patients to rapidly isolate neural progenitor cells, using our patented technology, to create Alzheimer’s disease in a dish cell models.
Diseases we are modelling with our iPG drug screening technology include familial and sporadic (late-onset) dementia, schizophrenia, epilepsy and other difficult to treat neurological conditions. We work with industrial pharmaceutical collaborators to test repurposed drug libraries, identify patient cohorts for inclusion within clinical trials and use our novel humanized network modelling technology to identify new disease targets and biomarkers. Our disruptive technology allows us to target the right patient with the right drug at the right time and will pave the way for optimal patient stratification for a range of difficult to treat neurological diseases/disorders and orphan diseases.
STRATASTEM Technology
- Permits robust differentiation of patient-derived iPSCs to all neuron and glial cell types
- Bypasses intrinsic species-dependent barriers between rodent models and humans
- Captures the genetic diversity of patient populations for product testing, lead optimisation and compound screening applications
- Our neurons-in-a-dish have the same genetic make-up and disease profiles as the corresponding disease-affected patients
- Enables testing on patient cells early in the discovery process rather than in clinical trials
- Provides scalable, comprehensive and mechanistic cellular models of disease pathology
Registered in England | Company Number: 08295004